The polymorphic gene expression of CYP2C19 causes individual variability in drug metabolism and thereby in pharmacologic and toxicologic responses. We genotyped 286 patients and their donors for the CYP2C19 gene who underwent allogeneic transplantation for various diseases and analyzed their outcome. Patients were classified as: poor metabolizers (PMs; 3.1%), intermediate metabolizers (IMs; 24.5%) and extensive metabolizers (EMs; 72.5%). Patients genotyped as PMs had significant higher hepato-and nephrotoxicities compared to IMs or EMs. Maximum bilirubin and serum creatinine levels measured after transplant were approximately twofold higher than those of EMs or IMs. The increased toxicity resulted in an increased 4-year estimate for transplant-related mortality (TRM) with 50718.6% for PMs compared to 25.173.7% for EMs (Po0.018) and 22.7 75.6% for IMs (Po0.042), whereas no significant influence for relapse rate, overall survival or incidence of acute graftversus-host disease grade 2-4 were found between the groups. Multivariate analysis including all potential factors that might influence TRM confirmed that the genotype of CYP2C19 is an independent factor, which influenced TRM significantly. These results suggest that genotyping for CYP450 2C19 can help to identify patients with higher risk for TRM.
Introduction
The polymorphic expression of drug-metabolizing enzymes is one of the major factors, which cause individual variability in drug metabolism and thereby in pharmacologic and toxicologic responses. One of the best characterized enzymes with a large number of genetic polymorphisms is cytochrome P450 (CYP) 2C19.
1 Previous studies on CYP2C19 using probe drugs such as S-mephenytoin showed that individuals could be classified into three different groups: poor metabolizers (PMs), intermediate metabolizers (IMs) and extensive metabolizers (EMs). PMs have a genetically determined absence of active enzymes, which is the cause for a slower metabolism of active drugs and is associated with prolonged side effects. 1 If prodrugs are applied, the metabolism in their active form is delayed and reduced effectiveness may occur. Among the drugs which are metabolized by CYP2C19 enzymes are cytostatics, proton pump inhibitors, antidepressants, sedative, beta blockers, antiviral and anti-fungal agents. [2] [3] [4] [5] [6] [7] [8] [9] Recently, it was demonstrated that PMs of CYP2C19 showed a decrease in platelet responsiveness to clopidogrel. 10 In another study, it was reported that patients treated with antidepressants and genotyped as PMs for CYP2D6 and CYP2C19, remained in hospital for longer (median 57.5 versus 40.0 days) compared to IMs. 8 Patients undergoing allogeneic transplantation are treated with more drugs, that is, immunosuppressives, chemotherapeutical agents or anti-infectious medication, each of them pivotal for the outcome of transplant. However, we hypothesized that altered drug metabolism in patients who underwent allogeneic transplantation might influence transplant outcome. In a retrospective single-center study, this paper evaluates whether gene polymorphisms of CYP2C19 enzyme influence the incidence of acute graftversus-host disease (GVHD) after transplant, and/or influence treatment-related mortality (TRM) and thereby the outcome of allogeneic stem cell transplantation.
Patients and methods

Patients
We included a total of 286 patients (and donors) for the CYP2C19 gene polymorphism analysis, who were transplanted at the University Hospital of Essen between October 1998 and December 2004. Genotyping was performed without knowledge of GVHD status or outcome of the patients analyzed. All aspects of this study were approved by the Institutional Review Board on Medical Ethics at the University Hospital of Essen.
Pre-transplant histocompatibility testing of patients and donors was performed at low-resolution human leukocyte antigen (HLA)-A, -B, -C and high-resolution HLA-DRB1, DQB1 level DNA-based typing according to standard methods. 11 
Conditioning regimen
The conditioning regimen consisted of intravenous cyclophosphamide in combination with fractioned total body irradiation (TBI) or oral busulfan (BU), in combination with cyclophosphamide or treosulfan in combination with cyclophosphamide or fludarabine as published earlier. 12 Patients who underwent transplantation of highly enriched CD34 þ cells received a conditioning regimen with fractioned TBI, cyclophosphamide and thiotepa as published earlier. 12 Patients scheduled for peripheral blood stem cell transplantation (PBSCT) with reduced conditioning received BU (1 mg/kg of body weight every 6 h over 2 days) in combination with fludarabine (30 mg/m 2 of body surface area over 5 days).
GVHD prophylaxis consisted of methotrexate (MTX) and cyclosporine (CSA) in patients who received an unmanipulated graft. 12 In the patients who underwent a CD34 þ -PBSCT, no further GVHD prophylaxis was given. In vivo T-cell depletion was performed using Campath-1 H (10 or 20 mg for 5 days) in combination with CSA or (rabbit) anti T-lymphocyte globuline (ATG-S, Fresenius, Bad Homburg, Germany) (10 mg/kg of body weight for 4 days) in combination with CSA and MTX.
Patient demographics are summarized in Table 1 .
Supportive care
All patients were isolated in reverse isolation rooms equipped with high-efficiency particular filtration systems and received prophylactic metronidazole 400 mg three times daily and oral ciprofloxacin, 750 mg twice daily and fluconazole, 200 mg once daily.
Clinical study endpoints
Neutrophil engraftment was defined as the first of three consecutive days with an absolute neutrophil count greater than 0.5 Â 10 9 /l. Acute GVHD was graded according to standard criteria. 13 Chronic GVHD was assessed in patients alive after 100 days. TRM was defined as death with no relapse. Overall survival (OS) was defined as survival from transplantation without death from any cause.
Diagnostic criteria for veno-occlusive disease Veno-occlusive disease (VOD) was suspected clinically according to the modified Seattle criteria which require the presence of at least two of the following three clinical findings before day þ 30 after hematopoietic stem cell transplantation (HSCT): (a) jaundice with bilirubin 434 mmol/l, (b) painful hepatomegaly and (c) fluid retention 45% of the body weight at the time of HSCT. In all patients, the diagnosis of VOD was confirmed either by demonstration of ascites and inversion of portal venous flow using Doppler sonography, or by liver biopsy or autopsy.
Analysis and measurement of blood parameters
Total bilirubin, g-glutamyl transferase, prothrombin time, activated partial thromboplastin, fibrinogen and creatinine were determined at baseline, and daily thereafter, until at least day þ 30 after HSCT. Weight and abdominal circumference were measured daily.
Isolation of genomic DNA DNA was prepared from peripheral blood mononuclear cells obtained from the donor and patient before the transplant using the phenol/chloroform method. 14 
Genotyping for CYP2C19
Polymorphisms of CYP2C19 were determined by use of the hybridization probe format (LightCycler CYP2C19 Mutation Detection Kit with specific primers; Roche Applied Science; Mannheim, Germany). Following genotypes were determined: CYP2C19*1/*1 (EMs); CYP2C19*1/*2 (IMs), CYP2C19*1/*3 (IMs), CYP2C19*2/*2 (PMs), CYP2C19*2/ *3 (PMs), CYP2C19*3/*3 (PMs). PCR and subsequent melting curve analysis were performed using the Lightcycler device (Roche Applied Science) and software. Control samples confirmed by sequencing were included in each run.
Definition of the study groups
Patients with wild type (EMs) of the analyzed gene were defined as group 1. Patients with heterozygous mutations (IMs) of the analyzed gene were designated as group 2, while patients with homozygous mutations (PMs) of the analyzed gene at the donor side only were named group 3. Besides these three groups, we also investigated the possible influence of donor genotype on patient outcome.
Statistics
Cumulative estimates (7standard errors) were calculated by the Kaplan-Meier method. 15 Differences between timeto-event distribution functions were compared by a logrank test (Mantel-Haenszel). 16 A stepwise proportional hazards general linear model (PHGLM) analysis was used to evaluate interactions of different covariates on the analytical endpoint of TRM. Covariates in PHGLM analyses were stratified according to severe acute GVHD, age (p40 or 440 years), gender constellation (male patient with female donor or other), PM (mutations at patient site) versus others, HLA-constellation between patient and donor, sibling donor versus unrelated donor, graft-type (PBSC or bone marrow), T-cell depleted graft versus non T-cell depleted graft, and disease stage (advanced versus early disease stages) were analyzed. Conditional risk ratios (RR) and their 95% confidence intervals (95% CI) were derived from PHGLM analyses after adjustment for significant covariates in the model. Statistical analysis was performed using the SPSS software version 12.0.
Only patients surviving for more than 30 days were included in the analysis of acute GVHD. A minimum of 100 days of follow-up was the criterion for chronic GVHD.
Results
Frequency of EMs, IMs and PMs
Of the patients 207 (72.4%) were genotyped as EMs, 70 (24.5%) as IMs and 9 (3.1%) as PMs. Of the donors, 204 (71.3%) were EMs and had a homozygous wild-type gene, 68 (23.8%) were genotyped as IMs and had a heterozygous genotype and 14 donors (4.8%) were typed as PMs with a homozygous gene mutation. Calculated allele frequencies did not differ much from those reported earlier by other studies for Caucasians, as shown in Table 2 .
17,18
Incidence of GVHD No statistic differences were found in the incidence of acute GVHD grade 2-4 for EMs, IMs and PMs with 28.2, 32.8 and 25%, respectively. The genotype of donors also had no significant influence on the incidence of GVHD grade 2-4 in patients. Patients with EM donors and those with IM donors did not differ statistically in the incidence of acute GVHD grade 2-4 (27.4 % EM versus 22.4% IM). There were also no differences found in the incidence of acute GVHD grade 2-4 for PM-patients with 25%. However, the highest incidence of acute GVHD grade 2-4 of 35.7% occurred in patients with PM-donors, although this was not statistically significant when compared to IMs or EMs. The incidence of chronic GVHD (extensive and limited together) was almost identical in the four study groups, with 73% in group 1, 68% in group 2 and 66% in group 3.
Influence of CYP2C19 gene polymorphism on hepatotoxicity and nephrotoxicity after transplant First, we compared the bilirubin and creatinine levels in PMs before transplant and defined them as baseline values. Thereafter, we evaluated the maximum bilirubin and creatinine values after transplant for all study groups. We found a more than threefold increase of bilirubin after transplant from baseline in PM patients (Po0.005). Serum creatinine also increased more than twofold from baseline after transplant as shown in Figures 1 and 2 . We then compared the maximum bilirubin and creatinine values of PMs with those of IMs and EMs. As expected, the highest maximum bilirubin and maximum creatinine levels after transplant were documented in PMs as shown in Figures 1  and 2 . The maximum bilirubin (median) was more than twofold higher than that of EMs and IMs (Po0.05). PMs had also the highest increase in serum creatinine levels compared to IMs and EMs.
VOD defined as mentioned above occurred slightly more often in PM-patients compared to the other study groups. VOD was diagnosed in 2 of 9 PM-patients (22%) and 5 of 38 IM-patients evaluated (13%) and 13 of 105 EM patients evaluated (12.4%), but these differences were not significant.
Treatment-related mortality, overall survival and occurrence of relapse Four-year estimate for TRM was highest in PM-patients with 50718.6% compared to EM patients (24.373.6% (Po0.018)) and IM patients 25.276.1% (Po0.042), whereas the 5-year estimate for relapse or OS was not statistically different between the groups. Four of the nine PM-patients died from TRM between days 50 and 174 after transplant. Causes of death were multi-organ failure, including liver and kidney involvement in combination with an opportunistic infection (Aspergillus pneumonia n ¼ 1, bacterial pneumonia n ¼ 2 and adenovirus infection n ¼ 1).
However, no differences in the 4-year estimates for TRM, relapse rate or OS were seen in patients with either EM, IM or PM donors (data not shown). Figure 3 shows TRM.
Engraftment Surprisingly, PM-patients had the fastest engraftment for neutrophils 4500 cells/ml with a median only 13 days (range 9-46) compared to IM-patients (median 16 days, range 9-33) or EM-patients (median 15 days, range 8-35), Abbreviations: CI ¼ confidence interval; n ¼ total number of alleles.
Loss-of-function allele of CYP2C19 and transplant-associated mortality AH Elmaagacli et al but these differences were not statistically significant. Donor genotype also had no influence on time of engraftment (data not shown). 
Multivariate analysis for TRM
Discussion
This study provides evidence that allogeneic transplantation in patients with a loss-of-function allele of CYP2C19 gene is associated with increased transplant-related hepatoand nephrotoxicities. Thus, we found a mean of twofold higher maximum total bilirubin and maximum creatinine levels in patients genotyped as PMs of CYP2C19 after transplant, compared to EMs with two active alleles, or IMs with only one active allele for CYP2C19. In consequence, and as hypothesized, the increased organ toxicity resulted in a markedly exaggerated TRM. Thus, our calculated 4-year TRM-estimates for PMs increased up to 50%, which is also approximately twofold higher than those of EMs and IMs with about only 23% (Po0.02 for PMs versus EMs, Po0.05 for PMs versus IMs). However, the current reported rate of TRM for EMs and IMs is in line with other studies concerning allogeneic transplants. 19 Furthermore, we found that in PMs the major cause for death was multi-organ failure in combination with opportunistic infection. The impact of genotype CYP2C19 (PMs versus others) on TRM defined as death other than relapse, was confirmed on a multivariate analysis considering all potential factors which influence TRM: patient age, HLAconstellation, sex-constellation between donor and patient, T-cell depletion, disease stage, occurrence of acute GVHD.
Although many drugs used in the transplant setting may induce exaggerated side effects in PMs and influence their outcome, cyclophosphamide plays a distinctive role in this setting with regard to toxicity. This cytostatic agent, widely used in conditioning regimens in combination with TBI or BU, is metabolized by CYP enzymes. 3, 4 It is often speculated that the broad interindividual variability of cyclophosphamide's side effects and clinical efficacy might be due to differences in pharmacokinetics. Recently, cyclophosphamide-kinetics were analyzed for functionally relevant polymorphisms of the CYP metabolizing enzymes CYP2B6, CYP2C9, CYP2C19, CYP3A5 and glutathione-S-transferase A1. 3 The results revealed that the CYP2C19*2 genotype (here defined as PMs) influenced pharmacokinetics of cyclophosphamide significantly, and thereby the serum concentrations of cyclophosphamide. Known side effects of cyclophosphamide are hepato-and nephrotoxicities. It is therefore possible that the slower metabolism of this cytostatic agent in PMs has an impact on the exaggerated TRM reported here. Six of the nine PM-patients studied here received high doses of cyclophosphamide as part of their conditioning regimen. In fact, of the six patients receiving high doses of cyclophosphamide, three died from multi-organ failure. It might be helpful to determine cyclophosphamide serum concentrations in PM-patients in future to avoid increased side effects.
Other prominent substrates of CYP2C19, which might potentially induce organ-toxicities and are widely used in the transplant setting, include proton pump inhibitors (PPI) such as omeprazole, lansoprazole or pantozole. Although extensive toxicities of PPI on liver and kidney are not so common, their side effects and thereby their influence on transplant outcome is not fully understood. It is reported in a different setting that their use in patients with different genotypes of CYP2C19 not only leads to varieties in measured gastric pH in these patients, but also causes differences in the eradication rate of helicobacter pylori when the combination of lansoprazole, amoxicillin and clarithromycin was used. Interestingly, the poorest eradication rate was found not in PMs, but in EMs. [5] [6] [7] All of our study-patients received omeprazole.
Moreover, little is known about organ toxicities caused by drug interactions involving metabolism of CYP2C19 enzymes. Some substrates of CYP2C19 are metabolized with a different affinity and by an alternative metabolic pathway than other CYP enzymes. Voriconazole, a potent antifungal drug, is such a substrate, which is metabolized by CYP2C19 and has a 50 times lower affinity for CYP3A4 enzymes. Coadministration of drugs with strong inhibitory effects on CYP3A4, such as ritonavir, a human immunodeficiency virus protease inhibitor, prevents metabolism of voriconazole by CYP3A4 enzymes and thereby leads to higher voriconazole concentrations with the risk of increased adverse events such as hepatotoxicity. 9 Indeed, hepatotoxicity is a dose-limiting adverse event in patients taking voriconazole, which is often observed. Moreover, clinically significant hepatic dysfunction occurs in more than 10% of patients receiving regular doses of voriconazole and is a major cause of discontinuation of this drug. 20 Studies conducted in Caucasian and Japanese healthy subjects have shown that PMs of CYP2C19 have, on average, a fourfold higher exposure to voriconazole than do their homozygous EM counterparts. Subjects who are heterozygous EMs experience, on average, a twofold higher voriconazole exposure than their homozygous EM counterparts. 21 Since many potentially CYP inhibiting drugs are often used in the transplant setting such as metoclopramide, norfloxacin, clarithromycin, fluconazole or itraconazole, it is possible that more adverse side events occur from drug interactions than is currently recognized.
As in other studies, we too did not determine the CYP2C19 activity phenotype here, since previous studies have already demonstrated that CYP2C19 genotyping identifies more than 90% of PMs, indicating good genotype-phenotype agreement. 22, 23 However, no differences were assessed in the rate of hepato-and nephrotoxicities between EMs and IMs. Furthermore, gene polymorphism of their donors including donors typed as PMs had no influence on patient outcome.
In conclusion, our study provides strong evidence that TRM and morbidity are influenced by gene polymorphisms of CYP2C19. Our results suggest that patients planned for allogeneic transplantation should be genotyped for CYP2C19 before transplant to identify those with a high individual risk of TRM. However, more studies concerning the role of gene polymorphisms of CYP are necessary.
